Sign in

    Paige Chamberlain

    Senior Equity Research Associate at Wolfe Research, LLC

    Paige Chamberlain is a Senior Equity Research Associate at Wolfe Research, LLC, specializing in medical supplies and devices analysis. She has contributed to coverage of leading industry players, working closely on sector research that supports Wolfe’s ranking as a top Wall Street firm, though individualized performance metrics such as TipRanks rankings or cumulative returns are not publicly available. Paige began her career as a Research Assistant before joining Wolfe Research in September 2022 as an Equity Research Associate and advancing to her current senior role in January 2025, with earlier experience as a marketing data analyst at Veeva Systems and research positions at Massachusetts Eye and Ear and Maine Medical Center Research Institute. She holds professional credentials including FINRA registration (CRD# 7631056) and has a strong background in data analytics and scientific research.

    Paige Chamberlain's questions to Nyxoah (NYXH) leadership

    Paige Chamberlain's questions to Nyxoah (NYXH) leadership • Q4 2024

    Question

    Paige Chamberlain, on for Mike Polark, questioned why Nyxoah is confident the Genio system fits under CPT code 64568, given the code's description includes a 'pulse generator'. She also asked about the new deferred revenue policy, specifically what portion of revenue will be deferred and if recognition depends on patient compliance.

    Answer

    CEO Olivier Taelman clarified that Genio does have a pulse generator, but it is external, which fits the code's description. CFO John Landry explained that a 'small percentage' of the selling price will be deferred and recognized as disposable patches are shipped, explicitly stating that recognition is not tied to patient compliance metrics.

    Ask Fintool Equity Research AI